Rely-AMP BCR-ABL P210

quantitative detection

Philadelphia chromosome is the result of a t(9;22) (q34;q11) reciprocal translocation and subsequent fusion of the c-ABL proto-oncogene on chromosome 9 with the BCR gene on chromosome 22.

Depending on the precise location of the fusion the molecular weight of the protein can range from 185 to 210 kDa. Two clinically important variants are the p190 and p210 isoforms. p190 is generally associated with  acute lymphoblastic leukemia (ALL), while p210 is generally associated with  chronic myeloid leukemia (CML) but can also be associated with ALL. Current guidelines from Europe Against Cancer (EAC) program and National Comprehensive Cancer Network (NCCN) recommend the use of quantitative real-time PCR to detect and quantify BCR-ABL expression before, during, and after treatment to assess the minimal residual disease (MRD) in patients with CML and ALL.

DETAILS

Rely-AMP BCR/ABL P210 is an in vitro Real Time polymerase chain reaction assay for the direct, quantitative detection p210 BCR-ABL mRNA. Housekeeping gene ABL is a reference for relative quantitation. Rely-AMP BCR/ABL P210 provides all necessary reagents for RNA extraction, reverse transcription and cDNA detection.

TECHNICAL SPECIFICATIONS

PERFORMANCE

Analytical sensitivity-detection limit: 1 leukemic cell/10⁵ normal cells 

Analytical Specificity: No cross-reactivity 

Diagnostic sensitivity: 96% 

Diagnostic specificity: 100%

Rely-AMP BCR-ABL P210

qualitative detection

DETAILS

Rely-AMP BCR/ABL  is an in vitro polymerase chain reaction assay for the direct detection BCR-ABL traslocation b3a2, b2a2, b2a3, b3a3. Rely-AMP BCR/ABL  provides all necessary reagents for RNA extraction, reverse transcription and cDNA detection.

TECHNICAL SPECIFICATIONS

ORDERING INFORMATION